This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MD Anderson Cancer Center Initiates Orders Of IsoRay's Cesium-131 For Intermediate Risk Prostate Cancer Study

Stocks in this article: ISR

IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, announced today that MD Anderson Cancer Center has initiated orders of Cesium-131 brachytherapy (internal radiation therapy) seeds as it continues its clinical research study investigating brachytherapy's ability to help control intermediate risk prostate cancer. “Intermediate risk” is a classification of early stage prostate cancer that has shown a tendency to recur following standard treatments including surgery and radiation therapy.

The current phase of the study will compare Cesium-131 to other, previously used isotopes. With other centers' prior successes using Cesium-131 in treating prostate cancer, principal investigator Dr. Steven J. Frank hopes to evaluate Cesium-131's effectiveness in addressing intermediate risk prostate cancer and its quality of life benefits. The study will also evaluate PSA response and the patient's return to urinary function baseline as well as normal lifestyle activities. High levels of PSA typically indicate the presence of prostate cancer.

Cesium-131 has a higher average energy than any other commonly used brachytherapy isotope and results in a more homogeneous dose. Other cancer centers' studies have demonstrated Cesium-131's ability to deliver the required radiation dose with excellent homogeneity across the entire prostate gland, while limiting damage to other tissue and body structures including the urethra and rectum.

IsoRay CEO Dwight Babcock says he believes this study will add to the growing recognition of Cesium-131's significant role as a powerful weapon in the fight against cancer. "Cesium-131 is already proving its essential value in fighting prostate cancers. My expectation is that this research study will be significant in identifying Cesium-131's improved cancer control for intermediate risk prostate cancer. I feel strongly that it will demonstrate Cesium-131's superiority over other isotopes and its ability to provide a faster return to urinary function baseline and normal daily activities." Babcock says that Cesium-131's full potential is just beginning to be realized as thought leaders seek solutions for treating cancers in other body sites. He pointed to its growing adoption in treating cancers throughout the body including recent exciting applications in treating Glioblastomas and metastasized brain cancer as well as lung cancers.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs